Anti-erythropoietin and anti-thrombopoietin antibodies induced after administration of recombinant human erythropoietin

Shin, Sug Kyun; Pack, Seung Pil; Oh, Jin-Gyo; Kang, Nak Heon; Chang, Myung Hee; Chung, Yoon Hee; Kim, Sung-Jo; Lee, Jong Wook; Heo, Tae‐Hwe

doi:10.1016/j.intimp.2011.10.014

Cited by 18 publications

(13 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our pilot study showed that nearly 16% of patients with T2DM had the anti-THPO antibody. Although we could not demonstrate the causality between the presence of the anti-THPO antibody and decreased platelet count in this study, a previous report indicated the direct effect of the anti-THPO antibody on thrombocytopenia [14]; in that study, the anti-THPO antibodies might have blocked the normal function of thrombopoietin and resulted in decreased platelet production.…”

Section: Discussioncontrasting

confidence: 80%

“…The distinct clinical features of autoimmune diseases, including type 1 DM and SLE were not evident in any of the patients. The anti-THPO antibody was reported to be found in patients with amegakaryocytic thrombocytopenic purpura [8], idiopathic thrombocytopenia purpura (ITP) [9], systemic lupus erythematosus (SLE) [10,11], in those treated with rhTHPO [12,13] and recombinant human erythropoietin [14]. In those reports, the anti-THPO antibody was assumed to be the cause of thrombocytopenia.…”

Section: Resultsmentioning

confidence: 99%

“…In those reports, the anti-THPO antibody was assumed to be the cause of thrombocytopenia. Shin SK et al [14] reported the inhibitory activity of the anti-THPO antibody against the interaction between rhTHPO and the THPO receptor. They also reported that, using the BaF3 cell expression of the THPO receptor, a serum was able to partially neutralize the proliferative activity of rhTHPO.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Pilot Study on the Effect of Anti-Thrombopoietin Antibody on Platelet Count in Patients with Type 2 Diabetes

et al. 2020

View full text Add to dashboard Cite

Thrombopoietin (THPO) is a circulatory cytokine that plays an important role in platelet production. The presence of anti-THPO antibody relates to thrombocytopenia and is rarely seen in hematopoietic and autoimmune diseases. To date, there had been no reports that focused on the anti-THPO antibody in patients with type 2 diabetes mellitus (T2DM). To evaluate prevalence of the anti-THPO antibody in patients with T2DM and the relationship between anti-THPO antibody and platelet count, a cross-sectional study was performed on 82 patients with T2DM. The anti-THPO antibody was measured by ELISA using preserved sera and detected in 13 patients. The average platelet count was significantly lower in patients with the anti-THPO antibody than in those without the anti-THPO antibody. Multivariate linear regression analyses showed a significant relationship between the anti-THPO antibody and platelet count, after adjusting for other variables. To our best knowledge, this was the first report on the effect of the anti-THPO antibody on platelet count in patients with T2DM. Further investigation is needed to validate the prevalence and pathological significance of the anti-THPO antibody in patients with T2DM.

show abstract

Section: Discussioncontrasting

confidence: 80%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Pilot Study on the Effect of Anti-Thrombopoietin Antibody on Platelet Count in Patients with Type 2 Diabetes

et al. 2020

View full text Add to dashboard Cite

show abstract

“…13,20,21 Therefore, serum anti-TPO antibodies were measured by enzyme-linked immunosorbent assay 4 weeks after the first dose, at the end of rhTPO treatment, and 6 months after delivery. 22 Given concerns about whether rhTPO could pass through the placenta, cord blood TPO levels were measured in neonates of healthy women and of patients with ITP treated with rhTPO, using enzyme-linked immunosorbent assay kits (R&D Systems) according to the manufacturer's instructions. Serum TPO levels in ITP mothers before and after rhTPO treatment were also measured to prove the measurability of exogenous TPO.…”

Section: Discussionmentioning

confidence: 99%

A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy

Kong

Qin

Xiao

et al. 2017

Blood

View full text Add to dashboard Cite

show abstract

“…Neuropathy will be de ned based on the diagnostic criteria for diabetic polyneuropathy proposed by the Diabetic Neuropathy Study Group [15]. The presence of retinopathy will be assessed from chart reviews.…”

Section: Secondary Outcomesmentioning

confidence: 99%

Usefulness of exercise for home blood pressure control in people with diabetes: A study protocol for a crossover randomized controlled trial

Iwai

Ushigome²,

Yokota

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The coexistence of hypertension and diabetes mellitus significantly increases the risk of macrovascular complications in patients with diabetes. Blood pressure at home is important because it is more strongly associated with target organ damage and total mortality than clinic blood pressure measurements. Regular moderate aerobic exercise has antihypertensive effects. This study aims to examine the effect of aerobic exercise therapy on blood pressure at home in patients with diabetes. Methods: In this crossover randomized controlled trial, 110 patients with type 2 diabetes will be randomly assigned to two groups: an exercise preceding group and an exercise lagging group. During the exercise period, patients will be instructed to walk either 30 minutes twice each day or 60 minutes once each day for at least three days per week. During the non-exercise period, patients will be permitted to perform physical activity associated with activities of daily life. Patients will be followed up for 56 days. The primary outcome will be the mean nocturnal blood pressure from day 24 to 28 during the exercise period compared to that during the non-exercise period. The secondary outcome will include variation in nocturnal blood pressure, mean blood pressure values and variation of morning and evening blood pressure from day 24 to 28 in the exercise period compared to the non-exercise period, body weight, body mass index and bioelectrical impedance analysis. Biochemical tests such as hemoglobin A1c level, blood glucose level, serum lipid profile, renal function, uric acid levels, liver function tests and urinary albumin excretion level will also be measured.Discussion: This randomized controlled trial will provide critical information regarding the effectiveness of moderate exercise on nocturnal blood pressure reduction. If successful, the results of this randomized controlled trial may increase exercise motivation in people with diabetes and may lead to improvement or prevention of target organ damage and overall mortality.Trial registration: Trial registration: University Hospital Medical Information Network, UMIN 000035973. Protocol version number: R000040969. Registration date: February 22, 2019. Recruitment began: June 19, 2019. The estimated date of completion of recruitment: March 31, 2021. URL: http://www.umin.ac.jp

show abstract

Anti-erythropoietin and anti-thrombopoietin antibodies induced after administration of recombinant human erythropoietin

Cited by 18 publications

References 13 publications

A Pilot Study on the Effect of Anti-Thrombopoietin Antibody on Platelet Count in Patients with Type 2 Diabetes

A Pilot Study on the Effect of Anti-Thrombopoietin Antibody on Platelet Count in Patients with Type 2 Diabetes

A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy

Usefulness of exercise for home blood pressure control in people with diabetes: A study protocol for a crossover randomized controlled trial

Contact Info

Product

Resources

About